Longevity for Women

Women outlive men in nearly every country on earth, by about 5 years on average globally. But those extra years often come with a painful catch. Women tend to spend more of that time in poor health. This gap between how long you live and how long you stay well is a core puzzle of women's longevity.

A few biological differences drive the split:

The XX chromosome advantage: Having two X chromosomes acts like a genetic backup. If a gene on one X is faulty, the other copy can step in. Men, with only one X, don't have that safety net. This helps explain why women tend to have stronger immune systems and lower rates of some genetic conditions.

Estrogen's protective role: Before menopause, estrogen quietly protects the heart and metabolism. It supports healthy cholesterol, keeps blood vessels flexible, builds bone density, and calms inflammation. When estrogen drops at menopause, that protection goes with it. That is a real turning point in how women age.

Autoimmune prevalence: The stronger female immune system has a downside. Women account for roughly 80% of autoimmune disease cases. Conditions like rheumatoid arthritis, lupus, and Hashimoto's thyroiditis hit women much harder and can eat into healthy years.

The healthspan gap: Women outlive men, but WHO and EU data consistently show women report more years with disability and chronic conditions. Closing that gap takes strategies built around how women actually age. One-size-fits-all longevity advice misses the mark.

Under-representation in geroscience trials (a real evidence gap): Several longevity-relevant clinical trials — early rapamycin pilots, metformin (TAME, which is designed for ~50/50 enrolment; recruitment status as of 2026 still pending under originally planned protocol), senolytics, GLP-1 longevity sub-studies — have skewed male in their early phases. Note: CALERIE Phase 2 was actually about 70% female (Kraus 2019), so it does not fit this pattern; many other early-phase mechanistic studies do. Sex-disaggregated outcomes are still the exception, not the rule in geroscience trial reporting; multiple analyses have flagged this gap. When you read longevity protocols originally validated on male cohorts, treat them as scaffolds requiring sex-aware adaptation: Blueprint, classical CR protocols, Attia's training prescriptions, and Huberman's cold/light protocols were all calibrated on male physiology first.

Hormonal change is the biggest biological event in how women age. Knowing the timeline and what it does to the body helps you get ahead of it.

The hormonal timeline:

• Perimenopause (typically ages 40 to 51): Estrogen and progesterone start swinging unpredictably. You may notice irregular periods, broken sleep, mood shifts, and hot flashes. This phase can last 4 to 10 years.
• Menopause (average age 51): Defined as 12 months in a row with no period. Estradiol (the main active estrogen) drops by roughly 90% from its peak. Estrone becomes the main estrogen still circulating after menopause.
• Post-menopause: The decades after, when low estrogen speeds up bone loss, raises heart risk, and shifts metabolism.

Hormone Replacement Therapy (HRT): The evidence on HRT has shifted a lot. The original Women's Health Initiative (WHI) study in 2002 flagged concerns about breast cancer and cardiovascular risk. But reanalysis of that data and newer studies paint a more nuanced picture:

• In subgroup analyses of WHI (Manson 2017), women who started HRT within 10 years of menopause showed a more favorable mortality trend, although the overall trial result was neutral (all-cause mortality HR 0.99). The timing hypothesis remains supported by NAMS/IMS guidelines but has not been confirmed by a powered RCT.
• Route and regimen matter more than the "bioidentical" label itself. Per the IMS 2024 White Paper and the NAMS 2022 position paper, transdermal estradiol carries a more favourable VTE/stroke profile than oral conjugated equine estrogens in observational data (E3N/ESTHER cohorts), and micronized progesterone shows a more favourable breast-cancer profile than older synthetic progestins like MPA. Direct RCT comparisons of progesterone formulations on breast-cancer endpoints are still missing — this preference is observational, not RCT-proven. Individualised prescribing remains the standard
• Absolute contraindications: current breast or hormone-sensitive cancer, prior unprovoked VTE or active thromboembolism, active coronary or cerebrovascular disease, unexplained vaginal bleeding, severe liver disease, known thrombophilia. Individual risk assessment is essential and should happen with a physician experienced in menopause care
• The benefits for bone health, hot flashes, and quality of life are well established

Thyroid connection: Women are 5 to 8 times more likely than men to develop thyroid problems. An underactive thyroid (hypothyroidism), common as women age, can look like menopause symptoms or make them worse. It can also speed up aging. Regular thyroid screening (TSH, free T4) matters, especially after age 35.

Beyond estrogen: DHEA and testosterone also fall off with age in women. Low testosterone shows up as less muscle, lower libido, and less energy. These hormones are getting more attention in full-picture hormone care.

Losing bone and muscle is one of the most serious parts of aging for women. The numbers hit hard: 1 in 3 women over 50 will break a bone from osteoporosis, versus 1 in 5 men. Hip fractures alone carry roughly 20–25% one-year mortality in older adults.

Why women are more vulnerable:

• Women start with lower peak bone mass than men
• The estrogen drop at menopause triggers fast bone loss. SWAN cohort data (Greendale 2012, PMC3378821) report cumulative transmenopausal bone loss of about 7.4% at the lumbar spine and 5.8% at the femoral neck over the ~3-year window bracketing the final menstrual period (≈2.5% and ≈1.9% per year) — accumulating to roughly 10.6% spine / 9.1% femoral neck over 10 years. Rates differ across racial/ethnic groups in SWAN — annualised percentage bone-loss patterns vary, with some analyses showing higher rates in Asian (Chinese, Japanese) women than in Caucasian or African American women, and absolute loss patterns depend on baseline BMD. Severe cases can run higher.
• Women live longer, so bone loss has more time to stack up

Strength training is non-negotiable: Lifting weights is the single most effective thing a woman can do for bones and muscle. It:

• Tells bones to grow by loading them mechanically
• Builds and keeps muscle (prevents sarcopenia, the age-related loss of muscle)
• Improves balance and cuts fall risk
• Helps metabolic health and insulin sensitivity

Research shows women who strength train 2 to 3 times a week can hold or even grow bone mineral density. Those who don't, progressively lose it.

Calcium and Vitamin D: The classic duo for bones. Women over 50 need about 1200 mg of calcium a day, ideally from food. Plus 1000 to 2000 IU of vitamin D3. Some practitioners also add Vitamin K2 on the theory that it directs calcium into bones rather than arteries, but the clinical outcome evidence is still mixed and major cardiovascular and bone-health bodies haven't adopted it as a standard recommendation.

Sarcopenia, the hidden threat: Muscle loss starts around age 30 and picks up speed after menopause. Women can lose 3 to 8% of muscle mass per decade after 30, with the rate climbing post-menopause. Eating enough protein (at least 1.2 g per kg of body weight) plus resistance training is the main defense.

Practical bone protection:

• Know the DEXA screening guidelines. The USPSTF recommends routine DEXA at 65, or earlier only if a fracture-risk assessment (e.g. FRAX) or risk factors (low body weight, prior fracture, steroid use, early menopause, family history) bring your risk up to that of a 65-year-old. A personal baseline earlier in menopause is a longevity-medicine preference, not standard care
• Put weight-bearing and resistance exercise first
• Hit your calcium, vitamin D, and protein targets
• Go easy on alcohol and skip smoking
• Talk to your doctor about medication options (like bisphosphonates) if bone density is low

Heart disease is the number one killer of women worldwide. Not breast cancer, as many assume. Yet heart disease in women is chronically underdiagnosed, undertreated, and underresearched.

The estrogen effect: Before menopause, estrogen keeps cholesterol ratios healthy, keeps blood vessels flexible, and calms inflammation. That is why heart attacks in pre-menopausal women are rare. After menopause, heart risk climbs sharply and the sex gap narrows. Absolute CVD mortality rates typically remain lower in women into the 60s and 70s, but the incidence curve accelerates.

Women present differently: Women often don't get the classic "crushing chest pain" during a heart attack. Instead, symptoms in women often look like:

• Shortness of breath
• Nausea or vomiting
• Back or jaw pain
• Extreme fatigue
• Dizziness

Because the pattern looks different, the diagnosis often gets missed or delayed. Women are more likely to be sent home from the ER with a missed heart attack.

Unique risk factors for women:

• A history of preeclampsia (roughly doubles CHD/stroke risk per Wu et al. 2017; the same meta-analysis reported ~4× higher incident heart failure, which the 2024 EHJ-QCCO update by Inversetti et al. (qcad065) revises downward toward ~2.5×) or gestational diabetes (around 1.5x higher overall cardiovascular disease risk)
• Polycystic ovary syndrome (PCOS)
• Early menopause (before age 40)
• Autoimmune conditions (chronic inflammation)
• Depression and chronic stress, which hit women disproportionately

What to do:

• Know your numbers: blood pressure, cholesterol (including Lp(a)), blood sugar, and hsCRP (a marker of inflammation)
• Make aerobic exercise a habit. Aim for 150 minutes moderate or 75 minutes vigorous each week
• Catch metabolic syndrome early. Watch waist size, triglycerides, and fasting glucose
• Don't brush off symptoms. Speak up if something feels off
• Talk heart risk with your doctor at menopause, not at 65

Nearly two-thirds of Alzheimer's patients are women. For decades, the explanation was simple: women live longer. But newer research shows biology also matters, not just lifespan.

Why women are more affected:

• The estrogen drop at menopause changes how the brain uses energy. PET scans show women's brains use less glucose during the menopausal transition. Cerebral blood flow and ATP production (the brain's energy currency) partly compensate. Preclinical research hints at a partial shift toward using ketones for fuel too.
• The APOE4 gene variant (the strongest genetic risk factor for Alzheimer's) raises risk much more in women than men between ages 65 and 75. That lines up with the decade right after menopause.
• Broken sleep during perimenopause and menopause hurts the brain's glymphatic system. That is the overnight cleaning crew that clears out amyloid plaques.
• Chronic stress and depression, both more common in women, are linked to a shrinking hippocampus and higher dementia risk.

Sleep is critical: Menopause and sleep feed into each other. Hot flashes wreck sleep, and bad sleep makes menopause symptoms worse. Protecting sleep during the menopausal transition is essential for the brain:

• Keep the bedroom cool (16 to 18 degrees Celsius, or 60 to 65 Fahrenheit)
• Stick to consistent sleep and wake times
• Cut off caffeine after noon
• Consider HRT if hot flashes are really breaking your sleep

Social connection as brain protection: Research consistently shows strong social networks are one of the most powerful protections against cognitive decline. Women tend to have larger social networks than men. That may partly explain their cognitive resilience even with higher Alzheimer's risk. Keeping friendships alive isn't just nice. It's a longevity strategy.

Proactive brain health strategies:

• Regular aerobic exercise, which boosts BDNF (brain-derived neurotrophic factor, a protein that keeps brain cells healthy)
• Keep learning, read, try new things
• Eat Mediterranean-style, especially omega-3 fats
• Manage stress
• Treat hearing loss. It's a risk factor for dementia you can change
• Fix sleep problems early, especially during perimenopause

Women's nutrition needs shift a lot across life stages. A generic plan misses key differences.

Iron, a shifting need: Pre-menopausal women need about 18 mg of iron a day to cover menstrual losses. After menopause, the need drops to 8 mg, same as men. Too much iron is pro-oxidant and may speed aging. Post-menopausal women should skip iron-fortified supplements unless a deficiency is confirmed.

Folate: Essential through the reproductive years for DNA building and methylation (a chemical tag that helps control how genes work). It matters for epigenetic health beyond childbearing too. Aim for 400 to 800 mcg a day, ideally from food (leafy greens, legumes, fortified grains). Either methylfolate (L-5-MTHF) or standard folic acid works for supplementation — the common claim that MTHFR carriers should universally avoid folic acid isn't supported by the CDC or major guidelines, and folic acid has the strongest trial evidence for preventing neural tube defects if you're planning a pregnancy.

Omega-3 fatty acids: DHA and EPA matter for heart, brain, and inflammation. Women may benefit from 1 to 2 grams of combined EPA and DHA daily, especially after menopause when estrogen's heart protection fades.

Protein, more than you think: Many women chronically under-eat protein. Research keeps pointing toward higher intake for aging women:

• Aim for at least 1.2 g per kg body weight daily (for example, 72 g for a 60 kg woman)
• Spread protein across meals. Hitting 30+ grams per meal kicks off muscle building more effectively
• Focus on leucine-rich sources: eggs, dairy, fish, poultry, soy

Phytoestrogens: Plant compounds (isoflavones in soy, lignans in flaxseed) that bind weakly to estrogen receptors. Research suggests they may ease mild menopause symptoms and support bones. Traditional Asian diets high in soy are associated with lower rates of osteoporosis and hot flashes. Genetics and lifelong exposure also play a role.

Other key nutrients:

• Calcium: 1200 mg a day after 50 (food sources preferred)
• Vitamin D: 1000 to 2000 IU daily. Test your levels each year
• Magnesium: 320 mg a day. Supports sleep, bones, and mood
• Vitamin K2: Often added alongside calcium and D3 on the theory that it directs calcium to bone rather than arteries. The mechanism is plausible, but human outcome data are still mixed — treat it as optional rather than essential
• B12: Absorption drops with age. Consider supplementing after 50

If one thing hits nearly every problem of female aging at once, it's exercise. Bone loss, muscle decline, heart risk, brain health, mood, metabolism. All respond to it. Yet exercise guidelines have historically been built around male bodies.

Strength training is the #1 priority: For women over 40, lifting weights is arguably more important than cardio. It hits the top threats head on: osteoporosis, sarcopenia, metabolic decline, and fall risk.

• Aim for 2 to 4 sessions a week
• Include compound lifts: squats, deadlifts, rows, presses
• Use progressive overload. Slowly add weight over time
• Don't fear heavy weights. Women have about 10% of men's testosterone and won't "bulk up" by accident

Zone 2 cardio for metabolic health: Low-intensity aerobic work (brisk walking, cycling, easy swimming at a conversational pace) builds mitochondrial capacity (how well your cells produce energy) and improves fat burning. It matters more after menopause, when metabolism tends to slow.

• Aim for 150 to 180 minutes per week
• Keep the pace where you can still talk
• Great for the heart without hammering your joints

Pelvic floor training: An often-overlooked piece of women's exercise. The pelvic floor supports bladder, uterus, and bowel function. Weakness here leads to urinary incontinence, which affects up to 50% of older women.

• Kegel exercises strengthen the pelvic floor
• Good breathing and core control while lifting protect pelvic floor health
• A pelvic floor physiotherapist can give you a personalized plan

Recovery differences: Women's recovery patterns differ from men's because of hormones:

• Women may handle higher training frequency but still need real recovery between heavy sessions
• Sleep quality drives recovery. Tackle menopause-related sleep problems
• Stress management matters. Cortisol blocks recovery and pushes belly fat storage
• Nutrition timing: protein within 1 to 2 hours after exercise helps muscle repair

A sample weekly framework:

• 2 to 3 strength training sessions (full body, or upper/lower split)
• 2 to 3 Zone 2 cardio sessions (30 to 45 minutes)
• Daily pelvic floor exercises
• 1 to 2 flexibility and mobility sessions (yoga, stretching)
• At least 1 rest day per week

The best time to start working on your longevity was 10 years ago. The second best time is today. Here's a practical roadmap:

First steps, this week:

• Start strength training, even with bodyweight at home
• Add an extra serving of protein to each meal
• Set a consistent sleep schedule

Within the first month:

• Book a full blood panel: metabolic panel, lipids, hsCRP, vitamin D, thyroid (TSH, free T4), iron/ferritin, HbA1c (average blood sugar over 3 months)
• Start a daily vitamin D supplement if you don't take one
• Start a 30-minute daily walk (Zone 2 cardio)

At your next doctor's visit:

• Talk through your heart risk profile, especially if you're near or past menopause
• Ask about HRT if menopause symptoms are bothering you. An informed conversation is your right
• Ask about DEXA timing. USPSTF recommends routine screening at 65, or earlier only if a fracture-risk assessment (FRAX) or risk factors (low weight, prior fracture, steroid use, early menopause, family history) bring your risk up to that of a 65-year-old. An earlier baseline at menopause is a longevity-medicine choice, not a standard guideline
• Go over any pregnancy complications (preeclampsia, gestational diabetes) as future heart risk flags

Markers to track over time:

• Bone density (DEXA every 2 years after menopause)
• Heart markers: blood pressure, LDL/HDL, triglycerides, Lp(a), hsCRP
• Metabolic health: fasting glucose, HbA1c, insulin
• Hormones: estradiol, FSH, thyroid panel, vitamin D
• Body composition: muscle mass, waist size

When to see a specialist:

• A menopause-trained gynecologist or endocrinologist for hormone care
• A pelvic floor physiotherapist if you deal with incontinence
• An endocrinologist if thyroid problems are suspected
• A cardiologist if you have pregnancy-related risk factors or a family history

One last thing. Women's longevity isn't just "longevity, but for women." It asks for real understanding of the biological, hormonal, and health realities women face. The science is moving fast. Being proactive today can reshape how well you live for decades.

Care quality for perimenopause and menopause varies widely across German-speaking countries. The right physician can make the difference between years of dismissed symptoms and a plan that actually works. Use the national society registers, then screen for clinical literacy on the phone.

Germany: The Deutsche Menopause Gesellschaft (DMG) maintains a physician register. Filter for certified "Menopause-Zentrum" or "Menopause-Sprechstunde." The best-trained group are Gynäkologen mit Zusatzbezeichnung Gynäkologische Endokrinologie und Reproduktionsmedizin. Large academic centres (Charité Berlin, LMU Munich, UKE Hamburg) often have dedicated menopause clinics.

Austria: The Österreichische Gesellschaft für Gynäkologie und Geburtshilfe (ÖGGG) maintains a menopause-expert list. Vienna has the densest network of menopause-trained gynaecologists.

Switzerland: The Schweizerische Menopause Gesellschaft (SMG) maintains a menopause-expert directory at menopause.ch; the Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) is the general gynaecology society and also lists practitioners. University hospitals in Zurich, Bern, Geneva, and Basel run specialised menopause consultations.

Red flag: A gynaecologist who reflexively refuses any HRT discussion by citing WHI 2002. The 2017 reanalysis and the North American Menopause Society 2022 position statement (now The Menopause Society as of 2024) substantially rehabilitated HRT for appropriate patients, particularly when started within the timing-hypothesis window (within 10 years of the last period, before age 60). A blanket "no" suggests the clinician hasn't updated their practice in two decades.

Green flags: Familiarity with transdermal estradiol versus oral routes, comfort prescribing micronized progesterone (Utrogest, Famenita), willingness to talk through the timing hypothesis and individual risk/benefit, and curiosity about symptoms beyond hot flashes (mood, cognition, joint pain, sleep architecture).

Once you have a menopause-literate physician, here is what standard care actually looks like in DACH pharmacies, so you know whether your prescription matches current best practice.

GKV-covered bioidentical combination (the default for most patients): Transdermal estradiol (Gynokadin Gel applied to skin, or Estramon transdermal patches) combined with oral micronized progesterone (Utrogest 100 mg or Famenita). Transdermal estradiol avoids first-pass liver metabolism, so it carries lower VTE and stroke risk than oral estradiol. Micronized progesterone is bioidentical and has a better profile for breast tissue and sleep than older synthetic progestins. Typical cost with Rezept: around €30 per quarter.

Non-standard compounded HRT: Estradiol or testosterone creams from Rezeptur-Apotheken, or DHEA and pregnenolone via specialised Internationale Apotheken in Germany. These are Selbstzahler prescriptions and costs vary considerably. Compounded hormones are not inherently superior to GKV-covered bioidenticals. The data support standard products.

Common prescribing patterns:

• Perimenopause with intact uterus: Estradiol continuously daily + progesterone 12-14 days per month (sequential). This typically produces a predictable monthly withdrawal bleed.
• Post-menopause (12+ months without a period): Continuous combined, estradiol daily + progesterone daily. No scheduled bleed.
• Post-hysterectomy: Estradiol alone, no progesterone needed.

Vaginal estradiol for local symptoms only: Ovestin creme (estriol), Oekolp, or the Estring slow-release ring. Useful for vaginal dryness, painful sex, and recurrent UTIs. Systemic absorption is minimal, so vaginal estradiol is generally considered safe even for women with contraindications to systemic HRT, including many breast cancer survivors (consult oncologist).

Many perimenopausal symptoms (fatigue, brain fog, low mood, weight gain) overlap with thyroid disease, iron deficiency, and early metabolic dysfunction. Running a proper baseline panel around age 40 separates what is hormonal from what is correctable through cheaper means.

Core panel to request from your Hausarzt or Gynäkologin:

• TSH + free T4: Thyroid dysfunction is common in women and mimics perimenopause symptoms closely. Screen regardless of symptoms.
• Ferritin and B12: Iron stores (not just hemoglobin) drive energy and cognition. Low ferritin (<50 ng/mL) is common in menstruating women and causes symptoms well before anaemia shows up. B12 absorption declines with age.
• 25-OH vitamin D: Target 30-50 ng/mL (75-125 nmol/L). DACH latitudes produce virtually no vitamin D from October to April.
• Fasting lipid panel including Lp(a): Standard lipids plus a one-time lifetime Lp(a) measurement. Lp(a) is largely genetic, remains stable across life, and is a strong independent cardiovascular risk predictor. Knowing your Lp(a) once informs lifetime risk stratification.
• HbA1c and fasting glucose: Early insulin resistance in perimenopause is common and often missed.
• AMH (anti-Müllerian hormone) if fertility is still relevant: FSH is unreliable in perimenopause because it fluctuates wildly across the cycle. AMH gives a more stable ovarian reserve estimate.
• Blood pressure, waist circumference, resting heart rate: Cheap, repeatable, and more predictive together than most lab values.

Bone baseline at 50 (a longevity-medicine choice, not standard screening): USPSTF recommends routine DEXA at 65, or earlier for women whose fracture risk matches a 65-year-old's (low weight, prior fragility fracture, steroid use, early menopause before 40, family history). Some longevity-oriented clinicians suggest an earlier personal baseline at menopause onset to track your own trend rather than just compare to the population — that's a preference, not a guideline. Insurance coverage reflects the guideline position: GKV typically reimburses DEXA only when a specific medical indication is present; ask your gynaecologist which apply to you.

When you walk into a gynaecology appointment, clinicians respond better to specific symptom clusters than to "I don't feel right." Use this decision tree to frame the conversation and know what to ask for.

Hot flashes + poor sleep: Discuss systemic HRT. The timing-hypothesis window (within 10 years of last period, before age 60) is when benefits most clearly outweigh risks for appropriate patients. Transdermal estradiol + micronized progesterone is the standard starting combination.

Vaginal dryness or painful sex alone (no other menopause symptoms): Ask about topical estradiol cream (Ovestin) or the Estring ring. Minimal systemic absorption, so the risk profile differs completely from systemic HRT. Often appropriate even when systemic HRT is not.

Mood changes, cognitive fog, broken sleep: Rule out thyroid dysfunction and iron deficiency first (TSH, free T4, ferritin). These often cause identical symptoms and are cheaper to fix. If labs are clean, then discuss HRT. Progesterone in particular can improve sleep architecture.

Bone density concerns or family history of fracture: Request a DEXA scan. Start calcium 1,000-1,200 mg/day from food where possible, D3 1,000-2,000 IU daily, K2 MK-7 100 mcg, and 2-3 strength training sessions per week. Bisphosphonates are reasonable only if DEXA T-score is below -2.5 or you've already had a fragility fracture. Do not jump to pharmacology for osteopenia alone; strength training does more.

Weight gain around menopause: Protein 1.6-2.0 g/kg body weight per day, resistance training 2-3x/week, maintain Zone 2 aerobic (150-180 min/week). Consider a continuous glucose monitor (Libre, Dexcom) for 2-4 weeks to see your individual postprandial glucose patterns. The foods that spike you are often not the ones you'd guess.

Heavy or unpredictable bleeding, bleeding after 12 months of amenorrhea: Not a longevity question. Book a gynaecologist appointment promptly. Post-menopausal bleeding needs endometrial evaluation.

The food side of postmenopausal bone and muscle protection is concrete. Here are realistic DACH-grocery-store targets per meal and per day.

Protein: 30 g per meal minimum: That is the threshold that reliably triggers muscle protein synthesis. Many women chronically under-hit at breakfast. Easy DACH combinations:

• 150 g Skyr or Magerquark (15-17 g protein)
• 3 eggs (18 g)
• 100 g chicken breast (23 g)
• 100 g cooked lentils (9 g, plus fibre)
• 30 g Parmesan or aged Gouda (10 g)
• 100 g Lachs or Hering (20 g)
• 200 g Tofu (16 g)

Combine two or three items per meal to reach 30 g reliably. Breakfast example: 150 g Skyr + 2 eggs + 30 g nuts = 38 g.

Calcium: 1,000-1,200 mg/day: Food-first. DACH staples deliver well: Quark, Skyr, natural yoghurt, Emmentaler, Gouda, Parmesan, sardines with bones, sesame seeds (Tahini), Grünkohl, Brokkoli, and fortified plant milks. 200 g Skyr + 40 g Emmentaler + a portion of Grünkohl easily covers the day. Use supplemental calcium only if you cannot meet the target through food.

Magnesium: 300-400 mg/day: Pumpkin seeds, sunflower seeds, Vollkornbrot, Haferflocken, dark chocolate (70%+), spinach, mandeln. Magnesium supports sleep, bone matrix, and insulin sensitivity. A small handful of pumpkin seeds daily plus a Vollkorn-heavy diet usually gets you there.

Vitamin D3 + K2: 1,000-2,000 IU D3 daily is a reasonable year-round dose for DACH latitudes — from October through April, vitamin D synthesis is effectively zero at German, Austrian, and Swiss latitudes. Adding 100 mcg K2 MK-7 is a common longevity-medicine add-on on the theory that it directs calcium to bone rather than arterial walls; the mechanism is plausible but human outcome data are still mixed, so treat K2 as optional rather than essential. Both are cheap and low-risk.

If you are taking or considering a GLP-1 receptor agonist (Ozempic, Wegovy, Mounjaro) while also on hormone therapy or oral contraceptives, the routes matter.

GLP-1s slow gastric emptying substantially, particularly during the first weeks after initiation and after dose increases. That delayed absorption can reduce the bioavailability of oral medications, including oral contraceptives and oral estradiol. The clinical significance varies by drug and by individual, but for oral contraceptives, manufacturers of tirzepatide explicitly recommend either switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting and after each dose escalation.

Practical implications:

• Transdermal estradiol is not affected by gastric emptying. Gynokadin Gel, Estramon patches, and Estreva work the same on a GLP-1 as off.
• Oral micronized progesterone (Utrogest, Famenita): Absorption may be modestly reduced during early GLP-1 use. If you started a GLP-1 recently and notice a return of sleep or mood symptoms, discuss timing or route with your gynaecologist.
• Oral combined contraceptives: Consider switching to a hormonal IUD, transdermal patch, or adding barrier backup during the first month of GLP-1 therapy and after each dose increase.

Talk to your gynaecologist before starting GLP-1 therapy while on oral hormones. The fix is usually straightforward (switch to a transdermal route or adjust timing), but it needs to be a deliberate conversation rather than a discovered problem. See our companion GLP-1 guide for full prescribing context in DACH.